Cargando…

Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein

BACKGROUND: Hepatitis C virus (HCV) genotype 3a is known to show comparatively better response to combination therapy than genotype 1 and 4. Mutations within NS5A gene of HCV have earlier been implicated with response to interferon (IFN) therapies in chronic HCV patients among various populations. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Ijaz, Khan, Sanaullah, Attaullah, Sobia, Khan, Shahid Niaz, Khan, Jabbar, Siraj, Sami, Iqbal, Aqib, Swati, Zahoor A, Idrees, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118205/
https://www.ncbi.nlm.nih.gov/pubmed/21609495
http://dx.doi.org/10.1186/1743-422X-8-258
_version_ 1782206436937302016
author Ali, Ijaz
Khan, Sanaullah
Attaullah, Sobia
Khan, Shahid Niaz
Khan, Jabbar
Siraj, Sami
Iqbal, Aqib
Swati, Zahoor A
Idrees, Muhammad
author_facet Ali, Ijaz
Khan, Sanaullah
Attaullah, Sobia
Khan, Shahid Niaz
Khan, Jabbar
Siraj, Sami
Iqbal, Aqib
Swati, Zahoor A
Idrees, Muhammad
author_sort Ali, Ijaz
collection PubMed
description BACKGROUND: Hepatitis C virus (HCV) genotype 3a is known to show comparatively better response to combination therapy than genotype 1 and 4. Mutations within NS5A gene of HCV have earlier been implicated with response to interferon (IFN) therapies in chronic HCV patients among various populations. As response to therapy are available in different populations because of the ethnic and viral factors and there was no study available on the phenomenon of resistivity to IFN. RESULTS: Chronic HCV 3a infected Pakistani patients were kept on IFN-α and ribavirin therapy for six months. NS5A gene of HCV was amplified and sequenced in the case of all the patients prior to therapy and the sequences were analysed for mutations. Out of the total 27 patients, 20 (74.07%) were observed with sustained virological response (SVR), 4 (14.81%) patients were non responder (NR) while 3 (11.11%) patients exhibited in end of treatment response (ETR). Three (3/20) (15%) SVR patients and two (2/3) ETR patients had mutations (ranging from I-V amino acids) within the NS5A ISDR regions. While the rest of the SVR patients (85%) and the NR had no mutations at ISDR region when compared with HCV K3a ISDR. CONCLUSIONS: Mutations within the NS5A gene of HCV 3a genotype may not influence the outcome of combination therapy in Pakistani populations.
format Online
Article
Text
id pubmed-3118205
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31182052011-06-19 Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein Ali, Ijaz Khan, Sanaullah Attaullah, Sobia Khan, Shahid Niaz Khan, Jabbar Siraj, Sami Iqbal, Aqib Swati, Zahoor A Idrees, Muhammad Virol J Research BACKGROUND: Hepatitis C virus (HCV) genotype 3a is known to show comparatively better response to combination therapy than genotype 1 and 4. Mutations within NS5A gene of HCV have earlier been implicated with response to interferon (IFN) therapies in chronic HCV patients among various populations. As response to therapy are available in different populations because of the ethnic and viral factors and there was no study available on the phenomenon of resistivity to IFN. RESULTS: Chronic HCV 3a infected Pakistani patients were kept on IFN-α and ribavirin therapy for six months. NS5A gene of HCV was amplified and sequenced in the case of all the patients prior to therapy and the sequences were analysed for mutations. Out of the total 27 patients, 20 (74.07%) were observed with sustained virological response (SVR), 4 (14.81%) patients were non responder (NR) while 3 (11.11%) patients exhibited in end of treatment response (ETR). Three (3/20) (15%) SVR patients and two (2/3) ETR patients had mutations (ranging from I-V amino acids) within the NS5A ISDR regions. While the rest of the SVR patients (85%) and the NR had no mutations at ISDR region when compared with HCV K3a ISDR. CONCLUSIONS: Mutations within the NS5A gene of HCV 3a genotype may not influence the outcome of combination therapy in Pakistani populations. BioMed Central 2011-05-25 /pmc/articles/PMC3118205/ /pubmed/21609495 http://dx.doi.org/10.1186/1743-422X-8-258 Text en Copyright ©2011 Ali et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ali, Ijaz
Khan, Sanaullah
Attaullah, Sobia
Khan, Shahid Niaz
Khan, Jabbar
Siraj, Sami
Iqbal, Aqib
Swati, Zahoor A
Idrees, Muhammad
Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title_full Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title_fullStr Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title_full_unstemmed Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title_short Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
title_sort response to combination therapy of hcv 3a infected pakistani patients and the role of ns5a protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118205/
https://www.ncbi.nlm.nih.gov/pubmed/21609495
http://dx.doi.org/10.1186/1743-422X-8-258
work_keys_str_mv AT aliijaz responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT khansanaullah responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT attaullahsobia responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT khanshahidniaz responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT khanjabbar responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT sirajsami responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT iqbalaqib responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT swatizahoora responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein
AT idreesmuhammad responsetocombinationtherapyofhcv3ainfectedpakistanipatientsandtheroleofns5aprotein